Patents Assigned to ZymoGenetics, Inc.
  • Publication number: 20140271645
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Application
    Filed: April 18, 2014
    Publication date: September 18, 2014
    Applicant: ZYMOGENETICS, INC.
    Inventors: Penny THOMPSON, Hal BLUMBERG, Yasmin A. CHANDRASEKHER, Julia E. NOVAK
  • Patent number: 8834879
    Abstract: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: September 16, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Publication number: 20140248661
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: April 2, 2014
    Publication date: September 4, 2014
    Applicant: ZymoGenetics Inc.
    Inventors: Scott R. Presnell, Francis J. Grant, Emily C. Costerison, Theodore E. Whitmore
  • Patent number: 8822642
    Abstract: Compositions and methods relating to soluble dimeric proteins are disclosed. The dimeric proteins comprise first and second polypeptide fusions linked via a dimerizing domain, each polypeptide fusion comprising first and second monomer domains corresponding to a cytokine or an extracellular domain of a cell-surface receptor. The monomer domains may be positioned amino terminal and carboxyl terminal to the dimerizing domain. Alternatively, the monomer domains may be positioned in tandem, either carboxyl terminal or amino terminal to the dimerizing domain. The dimeric proteins are useful in methods for therapy, diagnosis, and research.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: September 2, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Steven D. Levin, Margaret D. Moore, Craig D. Ostrander, Katherine E. Lewis, David W. Taft, Robert J. Rosler, Anitra Wolf, Megan M. Lantry
  • Patent number: 8816053
    Abstract: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: August 26, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Kevin M. Klucher, Wayne R. Kindsvogel, Pallavur V. Sivakumar, Katherine E. Henderson
  • Patent number: 8815238
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: August 26, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Patent number: 8808696
    Abstract: The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenström's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: August 19, 2014
    Assignees: Ares Trading S.A., Zymogenetics, Inc.
    Inventors: Herve Broly, Arnaud Ythier, Eric Sievers
  • Publication number: 20140220014
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 7, 2014
    Applicants: University of Washington, ZymoGenetics, Inc.
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
  • Patent number: 8790643
    Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: July 29, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
  • Patent number: 8784812
    Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 22, 2014
    Assignees: Zymogenetics, Inc., Ares Trading S.A.
    Inventors: Herve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
  • Patent number: 8778344
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: July 15, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
  • Publication number: 20140186346
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Yue YAO, Janine Bilsborough
  • Publication number: 20140186891
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicants: Merck Serono S/A, ZymoGenetics, Inc.
    Inventors: Kent BONDENSGAARD, Roland Beckmann
  • Publication number: 20140178333
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Application
    Filed: January 28, 2014
    Publication date: June 26, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Patent number: 8759066
    Abstract: Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: June 24, 2014
    Assignee: Zymogenetics, Inc.
    Inventors: Paul D. Bishop, Tracey A. Pownder, Paul O. Sheppard, Christopher J. Stenland
  • Patent number: 8759027
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 24, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
  • Patent number: 8734776
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: May 27, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Publication number: 20140141485
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 22, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • Patent number: 8728469
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: May 20, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher, Julia E. Novak
  • Publication number: 20140127206
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 8, 2014
    Applicant: ZYMOGENETICS, INC.
    Inventors: YUE YAO, JANINE BILSBOROUGH